The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial.

Nat Commun · 2024 · PMC10928173 · PMID 38467639

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In the randomized, double-blind, phase 3 KEYNOTE-240 study testing pembrolizumab versus placebo in the second line setting, OS and PFS did not reach statistical significance per specified criteria, but there was an improvement in ORR (18.3% versus 4.4%) 16 .

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.